Archives of Neuroscience

Published by: Kowsar

Long-Term Prophylaxis of Migraine

Francesco Raudino 1 , *
Author Information
1 Department of Neurology, Valduce Hospital, Como, Italy
Article information
  • Archives of Neuroscience: October 01, 2014, 1 (3); e19083
  • Published Online: October 1, 2014
  • Article Type: Research Article
  • Received: December 21, 2013
  • Revised: December 25, 2013
  • Accepted: December 29, 2013
  • DOI: 10.5812/archneurosci.19083

To Cite: Raudino F. Long-Term Prophylaxis of Migraine, Arch Neurosci. 2014 ; 1(3):e19083. doi: 10.5812/archneurosci.19083.

Copyright © 2014, Tehran University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Gallai V, Sarchielli P. Diagnostic and therapeutic guidelines for migraine. Italian Society for the Study of Headaches (SISC). J Headache Pain. 2001; 2(1)[DOI]
  • 2. Lewis D, Ashwal S, Hershey A, Hirtz D, Yonker M, Silberstein S, et al. Practice parameter: pharmacological treatment of migraine headache in children and adolescents: report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society. Neurology. 2004; 63(12): 2215-24[PubMed]
  • 3. Members of the task, force , Evers S, Afra J, Frese A, Goadsby PJ, Linde M, et al. EFNS guideline on the drug treatment of migraine - report of an EFNS task force. Eur J Neurol. 2006; 13(6): 560-72[DOI][PubMed]
  • 4. Pryse-Phillips WE, Dodick DW, Edmeads JG, Gawel MJ, Nelson RF, Purdy RA, et al. Guidelines for the diagnosis and management of migraine in clinical practice. Canadian Headache Society. CMAJ. 1997; 156(9): 1273-87[PubMed]
  • 5. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000; 55(6): 754-62[PubMed]
  • 6. Management of migraine. Guidelines for All Healthcare Professionals in the Diagnosis and Management of Migraine, Tension-Type, Clusture and Medication-Overuse Headache. 2007;
  • 7. Headache and facial neuralgia. treatment recommendations. 2010;
  • 8. Graud G, Lantri-Minet M, Lucas C, Valade D. French guidelines for the diagnosis and management of migraine in adults and children. Clin Ther. 26(8): 1305-18[DOI]
  • 9. Steiner TJ, Paemeleire K, Jensen R, Valade D, Savi L, Lainez MJ, et al. European principles of management of common headache disorders in primary care. J Headache Pain. 2007; 8 Suppl 1-47[DOI][PubMed]
  • 10. Rapoport A, Mauskop A, Diener HC, Schwalen S, Pfeil J. Long-term migraine prevention with topiramate: open-label extension of pivotal trials. Headache. 2006; 46(7): 1151-60[DOI][PubMed]
  • 11. Diener HC, Agosti R, Allais G, Bergmans P, Bussone G, Davies B, et al. Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2007; 6(12): 1054-62[DOI][PubMed]
  • 12. Pascual J, El Berdei Y, Gomez-Sanchez JC. How many migraine patients need prolonged (>1 year) preventive treatment? Experience with topiramate. J Headache Pain. 2007; 8(2): 90-3[DOI][PubMed]
  • 13. Headache Classification Subcommittee of the International Headache S. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004; 24 Suppl 1: 9-160[PubMed]
  • 14. Linde K, Rossnagel K. Propranolol for migraine prophylaxis. Cochrane Database Syst Rev. 2004; (2)[DOI][PubMed]
  • 15. Diamond S, Kudrow L, Stevens J, Shapiro DB. Long-term study of propranolol in the treatment of migraine. Headache. 1982; 22(6): 268-71[PubMed]
  • 16. Wober C, Wober-Bingol C, Koch G, Wessely P. Long-term results of migraine prophylaxis with flunarizine and beta-blockers. Cephalalgia. 1991; 11(6): 251-6[PubMed]
  • 17. Bono G, Manzoni GC, Martucci N, Baldrati A, Farina S, Cassabgi F, et al. Flunarizine in common migraine: Italian cooperative trial. II. Long-term follow-up. Cephalalgia. 1985; 5 Suppl 2: 155-8[PubMed]
  • 18. Martinez-Lage JM. Flunarizine (Sibelium) in the prophylaxis of migraine. An open, long-term, multicenter trial. Cephalalgia. 1988; 8 Suppl 8: 15-20[PubMed]
  • 19. Colucci D'Amato C, Colucci D'Amato A, Alfano V, Giordano E, Marmo E. Flunarizine in long-term migraine prophylaxis: clinical evidence. J Med. 1990; 21(3-4): 201-7[PubMed]
  • 20. Nuti A, Lucetti C, Pavese N, Dell'Agnello G, Rossi G, Bonuccelli U. Long-term follow-up after flunarizine or nimodipine discontinuation in migraine patients. Cephalalgia. 1996; 16(5): 337-40[PubMed]
  • 21. Silberstein SD, Collins SD. Safety of divalproex sodium in migraine prophylaxis: an open-label, long-term study. Long-term Safety of Depakote in Headache Prophylaxis Study Group. Headache. 1999; 39(9): 633-43[PubMed]
  • 22. Nelles G, Schmitt L, Humbert T, Becker V, Sandow P, Bornhoevd K, et al. Prevention of episodic migraines with topiramate: results from a non-interventional study in a general practice setting. J Headache Pain. 2010; 11(1): 33-44[DOI][PubMed]
  • 23. Steiner TJ, Findley LJ, Yuen AW. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalalgia. 1997; 17(2): 109-12[PubMed]
  • 24. Gupta P, Singh S, Goyal V, Shukla G, Behari M. Low-dose topiramate versus lamotrigine in migraine prophylaxis (the Lotolamp study). Headache. 2007; 47(3): 402-12[DOI][PubMed]
  • 25. Jackson JL, Shimeall W, Sessums L, De Zee KJ, Becher D, Diemer M, et al. Tricyclic antidepressants and headaches: systematic review and meta-analysis. BMJ. 2010; 341[DOI]
  • 26. Granella F, Cavallini A, Sandrini G, Manzoni GC, Nappi G. Long-term outcome of migraine. Cephalalgia. 1998; 18 Suppl 21: 30-3[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments